Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raxone long-term treatment in Leber hereditary optic neuropathy
2015-004405-16Phase 4Completed
- Sponsor
- Santhera Pharmaceuticals
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of idebenone in Leber hereditary optic neuropathy (LHON) (2 arms), sponsored by Santhera Pharmaceuticals. Primary endpoint: Clinically relevant visual acuity recovery or maintenance at Month 12 in patients treated within 1 year of symptom onset. Started Feb 2016; status: completed.
02
Drugs
idebenone
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on 2015-004405-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004405-16.